Search Within

Solid Tumor Oncology Division

Formats
  1. Journal Article (10933)
  2. Meeting Abstract (9499)
  3. Review (557)
  4. Book Section (417)
  5. Editorial (336)
  6. Guidelines (158)
  7. Correspondence (118)
  8. Conference Paper (107)
  9. Research Letter (61)
  10. Miscellaneous (54)
  11. Book Whole (27)
Groups
  1. Department of Medicine (22244)
  2. GSK Faculty (5930)
  3. Genitourinary Oncology Service (5651)
  4. Survivorship Research (5226)
  5. Gastrointestinal Oncology Service (4692)
  6. Breast Medicine Service (4156)

More Groups

People
  1. Robert Motzer (1247)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (872)
  6. Leonard Saltz (792)

More People

Years
  1. 2025 (644)
  2. 2024 (1388)
  3. 2023 (1381)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1536)

More Years

Publications
  1. Journal of Clinical Oncology (5288)
  2. Annals of Oncology (1297)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (776)
  5. Journal of Thoracic Oncology (532)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5580)
  2. Elsevier Inc. (2662)
  3. American Association for Cancer Research (2327)
  4. Oxford University Press (1819)
  5. Nature Publishing Group (1044)
  6. Springer (982)

More Publishers

Results (22267)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Health-related quality of life (HRQOL) results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer
    Meeting Abstract

    Chen, R. C.; Mazza, G. L.; Fruth, B.; Xiao, H.; Picus, J.; Taplin, M. E.; Dorff, T. B.; Appleman, L. J.; Weckstein, D. J.; Patnaik, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1/2, safety lead-in and dose expansion, open-label, multicenter trial investigating the safety, tolerability, and preliminary activity of ivosidenib in combination with nivolumab and ipilimumab in previously treated subjects with IDH1-mutated nonresectable or metastatic cholangiocarcinoma
    Meeting Abstract

    Kelley, R. K.; Cleary, J. M.; Sahai, V.; Baretti, M.; Bridgewater, J. A.; Hua, Z.; Gliser, C.; Bian, Y.; Abou-Alfa, G. K.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non-small-cell lung cancer (NSCLC)
    Meeting Abstract

    Lee, J. M.; Spicer, J.; Nair, S.; Khattak, A.; Brown, M.; Meehan, R. S.; Shariati, N. M.; Deng, X.; Samkari, A.; Chaft, J. E.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6) -directed antibody-drug conjugate, in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors
    Meeting Abstract

    Spira, A. I.; Lee, E. K.; O'Cearbhaill, R. E.; LoRusso, P.; Falchook, G. S.; Patel, M. R.; Richardson, D. L.; Lu, W.; Marreddy, P.; Farrington, D. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Association of machine learning (ML)-derived histological features with transcriptomic molecular subtypes in advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Beig, N.; Nofallah, S.; McDermott, D. F.; Motzer, R. J.; Powles, T.; Rini, B. I.; Koeppen, H.; Banchereau, R.; Markey, M.; Finberg, I.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Multi-institution real world analysis of patients with non-small cell lung cancer (NSCLC) treated with standard of care (SOC) neoadjuvant chemo-immunotherapy (chemoIO)
    Meeting Abstract

    Cooper, A. J.; Gorria, T.; Conroy, M. R.; Ricciuti, B.; Pecci, F.; Aldea, M.; Anagnostou, V.; Shaverdian, N.; Bott, M.; Forde, P. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 2 study of livmoniplimab in combination with budigalimab in patients with hepatocellular carcinoma
    Meeting Abstract

    Abou-Alfa, G. K.; Chiu, C. F.; Piscaglia, F.; Sangro, B.; Henkel, A.; Fang, H.; Patel, M.; Ping, Z.; Sutherland, C.; Bako, E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 ((225)Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Morris, M. J.; Wong, J. Y. C.; Nordquist, L.; Szmulewitz, R. Z.; Agarwal, N.; Attiyeh, E. F.; Max, S. I.; Divgi, C. R.; Patricia, D.; Cao, Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Alignment of patient-clinician perspectives in triple-negative breast cancer (TNBC)
    Meeting Abstract

    Ackbarali, T.; Goins, C.; Walker, S.; Donahue, S.; Witt, J.; Vidal, G. A.; Traina, T. A.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Alliance EAY191-A6: FOLFOX in combination with binimetinib as second-line therapy for patients with advanced biliary tract cancers (BTCs) with MAPK pathway alterations: A ComboMATCH treatment trial
    Meeting Abstract

    Shergill, A.; Liao, C. Y.; Elsaid, M. I.; Al Baghdadi, T.; Ji, Y.; Feldman, D.; George, S.; O'Reilly, E. M.; Meyerhardt, J. A.; Berg, S. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save